🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05623124
Recruiting Observational

Ruijin Neurobank of Alzheimer's Disease and Dementia

NCT05623124 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Observational
Started
2021-11-22
Last updated
2024-11-25

Condition(s) studied

Dementia

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

The goal of this observational study is to learn about neuroimage and biomarkers in the Alzheimer's continuum. The main questions it aims to answer are:

* How is the neurovascular coupling during AD pathogenesis?
* How is the pattern/mapping of alterations in AD biomarkers? Participants will be observed and visit the research center annually to perform multi-modal MRI, PET, neuropsychological tests, and blood tests.

Eligibility

Sex
ALL
Min age
50 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Male and female aged 50 to 90 years old; 2. In accordance with the diagnostic criteria for "mild cognitive impairment due to Alzheimer's disease" and "Dementia" from the National Institutes of Health National Institute on Aging-Alzheimer's Association (NIA-AA) (2011); 3. The Hamilton depression rating scale/17 edition (HAMD) total score\<10; 4. The clinical dementia rating (CDR) is 0.5 or above; 5. Neurological examination: no obvious signs; 6. Participants should have a caregiver stable and reliable. 7. Education: primary school (grade 6) or above. They have the ability to complete tests for cognitive ability and have the ability and time to complete regulation of cognitive training Exclusion Criteria: 1. Other causes of cognitive decline: cerebrovascular disease, central nervous system infection, CJD, Huntington's and Parkinson's disease, DLB, traumatic brain dementia, other physical and chemical factors (such as drugs, alcohol, CO), systemic disease (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a subdural hematoma, brain tumor), the endocrine system disease (thyroid disease, parathyroid disease), and vitamins deficiency or any other causes of dementia. 2. The history of nervous system diseases, including stroke, optic myelitis, Parkinson's disease, epilepsy, etc.); 3. Psychiatric patients, including schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium; 4. There are unstable or serious heart, lung, liver, kidney, and hematopoietic system diseases; Poor prognosis because of malignant diseases such as tumors. 5. Vision or hearing problems that lead to poor performance on cognitive tests; 6. Two years history of severe alcoholism, and drug abuse; 7. The researchers believe that the subjects could not complete the study. 8. Contraindication of MRI or PET scanning.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine Shanghai Shanghai Municipality Recruiting

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05623124 on ClinicalTrials.gov ↗ ← All trials in China